ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $0.24 per share for the 12-month period ending 2017-06-30, per its 10-K filed 2017-10-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2017-10-13
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2017 was $0.24, a 40.00% decline from fiscal 2016.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2016 was $0.40, a 49.37% decline from fiscal 2015.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2015 was $0.79.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2017-06-30 | $0.24 10-K · filed 2017-10-13 |
| 2016-06-30 | $0.40 10-K · filed 2016-10-13 |
| 2015-06-30 | $0.79 10-K · filed 2015-10-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |